Sandoz announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed rituximab biosimilar. The drug is referenced on Rituxan, which is approved to treat blood cancers and immunological diseases.
Sandoz announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed rituximab biosimilar. The drug is referenced on Rituxan, which is approved to treat blood cancers and immunological diseases.
The BLA’s data package includes analytical, preclinical, and clinical data, including a pharmacokinetic and pharmacokinetic trial of the proposed drug in the ASSIST-RA rheumatoid arthritis trial phase 3 confirmatory safety and efficacy data from the ASSIST-FL follicular lymphoma study.
Sandoz says that it hopes its drug will, if approved, help reduce the high cost of biologic treatment. “The cost of treating cancer in the [United States] is a major concern for many patients and their families as well as for the healthcare system,” said Mark Levick, MD, PhD, global head of biopharmaceuticals development for Sandoz. “With the FDA acceptance of our regulatory submission for proposed biosimilar rituximab, we plan to…[free] up resources for and [support] patient access in other areas of cancer care including innovative therapies.”
In June, Sandoz received approval from the European Commission to market its rituximab biosimilar in Europe. Under the name Rixathon, Sandoz’s product is approved to treat all indications of the reference rituximab. Sandoz called the product 1 of 5 major launches the company has planned for the coming 4 years.
While the reference rituximab already faces competition from biosimilars in Europe, the global market for the drug has continued to grow; the branded drug earned $8.58 billion for Genentech in 2016, an increase of 2.7% from its 2015 sales.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.